AbbVie Inc. buy hoffi69
Summary
This prediction ended on 10.11.14 with a price of €51.03. The BUY prediction by hoffi69 finished with a performance of 17.28%. hoffi69 has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
AbbVie Inc. | -1.958% | -1.958% | 11.928% | 55.888% |
iShares Core DAX® | 4.094% | 3.543% | 17.404% | 20.326% |
iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% | 55.365% |
iShares Nikkei 225® | -1.572% | -4.633% | 15.731% | 2.146% |
iShares S&P 500 | 1.822% | 0.963% | 30.396% | 45.950% |
Comments by hoffi69 for this prediction
In the thread AbbVie Inc. diskutieren
Aktienrückkauf
"Der US-Pharmakonzern Abbvie plant nach der abgeblasenen Übernahme des irisch-britischen Konkurrenten Shire einen großen Aktienrückkauf. In den kommenden Jahren werde Abbvie eigene Papiere für fünf Milliarden US-Dollar zurückkaufen, teilte das Unternehmen am Montag mit. Außerdem soll die Quartalsdividende um 17 Prozent auf 0,49 US-Dollar steigen."
Quelle: dpa-AFX